5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Temozolomide - Gastrointestinal Stromal Tumors, Sdh | Phase 2 | Completed | Adam Burgoyne, MD, PhD | 23 | 2018-09-12 | 2026-07-28 |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Vandetanib - GIST | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2013-12-14 | 2020-03-30 |
| A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Ponatinib - GIST | Phase 2 | Completed | Ariad Pharmaceuticals | 45 | 2013-06-05 | 2018-05-18 |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) Pazopanib, Best supportive care - GIST | Phase 2 | Completed | Centre Leon Berard | 81 | 2011-03-01 | 2016-02-25 |
| An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) BIIB021 - GIST | Phase 2 | Completed | Biogen | 20 | 2008-02-01 | 2015-10-02 |
Gastrointestinal Stromal Tumors (2) · Gastrointestinal Neoplasms (1) · Hematoma, Subdural (1) · Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Connective and Soft Tissue (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Craniocerebral Trauma (1) · Gastrointestinal Neoplasms (1) · Hematoma (1) · Hemorrhage (1) · Intracranial Hemorrhage, Traumatic (1)
6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (1) · Temozolomide (1) · pazopanib (1) · ponatinib (1) · vandetanib (1)
Adam Burgoyne, MD, PhD (1) · Ariad Pharmaceuticals (1) · Biogen (1) · Centre Leon Berard (1) · National Cancer Institute (NCI) (1)
United States (4) · France (1)
Adam Burgoyne, MD, PhD (1) · Brigitte C Widemann, M.D. (1) · Jason Sicklick, MD (1)